SESSION 1
- Microbiome and immune system in cancer – Laurence Zitvogel (Gustave Roussy, Paris, France)
- Microbiota-mediated metabolic health – Soraya Taleb (Paris-Centre de Recherche Cardiovasculaire, Paris,France)
- Shaping of adaptive immunity by the microbiota – Hyun-Dong Chang (Deutsches Rheuma-Forschungszentrum Berlin, Germany)
- Effects of non-antibiotics on the microbiome – Georg Zeller (EMBL Heidelberg, Germany)
SESSION 2
- Potential of fecal microbiota for early-stage detection of colorectal cancer – Georg Zeller (EMBL Heidelberg, Germany)
- Crosstalk of the microbiome and epithelial cells – Dirk Haller (Technische Universität München, Germany)
- Regulation of life span by the gut microbiome – Dario Valenzano (Max Planck Institute for Biology of Ageing, Germany)
- Applying systems-biology to study the mechanistic interactions of the gut microbiota – Naama Geva-Zatorsky (Technion, Israel)
- Gut microbiota-derived propionate reduces cancer cell proliferation in the liver – Laure Bindels (Université Catholique de Louvain, Belgium)
- Microbiome restoration therapy in acute myeloid leukemia – Ronald Carter (Maat-Pharma, France)
SESSION 3
- Microbiome and immunotherapy in cancer – Giorgio Trinchieri (Center for Cancer Research/NCI/NIH, USA)
- Interplay of innate lymphoid cells and the microbiota – Andreas Diefenbach (Charité – Universitätsmedizin Berlin, Germany)
- The role of microbiota in GvHD and complications of allogeneic SCT – Ernst Holler (Universitätsklinikum Regensburg, Germany)
- The intra-tumoral bacterial flora – potential implications – Mark Tangney (University College Cork, Ireland)
SESSION 4
- Monoclonal microbials and cancer therapy– Mark Bodmer (Evelo Biosciences, USA)
- Establishing fecal microbiota transfer in Germany – a steep and stony path – Maria Vehreschild (University Hospital Cologne, Germany)
- Challenges in regulating microbiota – Anja Düchting (BfArM, Germany)
- Enhancement of anti-tumor immunity via targeted alteration of the microbiome – Bernat Olle (Vedanta Biosciences, USA)